Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; A Coats; LIFE study group

doi:10.1016/S0140-6736(02)08089-3

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, Stevo Julius, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristiansson, Ole Lederballe-Pedersen, Lars H Lindholm, Markku S Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, A Coats, LIFE study group

Faculty of Medicine and Health Sciences

Research output: Contribution to journal › Article

4902 Citations (Scopus)

Original language	English
Pages (from-to)	995-1003
Number of pages	9
Journal	The Lancet
Volume	359
Issue number	9311
DOIs	https://doi.org/10.1016/S0140-6736(02)08089-3
Publication status	Published - 2002

Access to Document

10.1016/S0140-6736(02)08089-3

http://dx.doi.org/10.1016/S0140-6736(02)08089-3

Cite this

Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Coats, A., & LIFE study group (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet, 359(9311), 995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3

@article{c35bca5eea58491ab81f9dfbaaa48197,

title = "Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol",

author = "Bj{\"o}rn Dahl{\"o}f and Devereux, {Richard B} and Kjeldsen, {Sverre E} and Stevo Julius and Gareth Beevers and {de Faire}, Ulf and Frej Fyhrquist and Hans Ibsen and Krister Kristiansson and Ole Lederballe-Pedersen and Lindholm, {Lars H} and Nieminen, {Markku S} and Per Omvik and Suzanne Oparil and Hans Wedel and A Coats and {LIFE study group}",

year = "2002",

doi = "10.1016/S0140-6736(02)08089-3",

language = "English",

volume = "359",

pages = "995--1003",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9311",

}

Dahlöf, B, Devereux, RB, Kjeldsen, SE, Julius, S, Beevers, G, de Faire, U, Fyhrquist, F, Ibsen, H, Kristiansson, K, Lederballe-Pedersen, O, Lindholm, LH, Nieminen, MS, Omvik, P, Oparil, S, Wedel, H, Coats, A & LIFE study group 2002, 'Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol', The Lancet, vol. 359, no. 9311, pp. 995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3

TY - JOUR

T1 - Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

AU - Dahlöf, Björn

AU - Devereux, Richard B

AU - Kjeldsen, Sverre E

AU - Julius, Stevo

AU - Beevers, Gareth

AU - de Faire, Ulf

AU - Fyhrquist, Frej

AU - Ibsen, Hans

AU - Kristiansson, Krister

AU - Lederballe-Pedersen, Ole

AU - Lindholm, Lars H

AU - Nieminen, Markku S

AU - Omvik, Per

AU - Oparil, Suzanne

AU - Wedel, Hans

AU - Coats, A

AU - LIFE study group

PY - 2002

Y1 - 2002

U2 - 10.1016/S0140-6736(02)08089-3

DO - 10.1016/S0140-6736(02)08089-3

M3 - Article

VL - 359

SP - 995

EP - 1003

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9311

ER -